ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. Using our proprietary discovery platform for targeted (epiotope-specific) immunotherapy, ImmusanT is developing a therapy and personalized diagnostics for celiac disease and is expanding to other autoimmune diseases including Type 1 diabetes.
December 22, 2014
ImmusanT Raises $12 Million in Series B Financing
One Kendall Square
Cambridge, MA 02139